StockData
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX) stock

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)

Close on Nov 17, 2026Market cap $206.32MP/E –Yield –

Lineage Cell Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Lineage Cell Therapeutics's pe ratio was 3.8× on Oct 31, 2019, against 2.8× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2019Oct 31, 20193.8×−3.2
2018Jan 31, 20186.9×+1.8
2017Dec 29, 20175.1×−12.1
2016Dec 30, 201617.2×–

More Lineage Cell Therapeutics figures

See a number that looks wrong?